The clinical logic behind the femoral approach is straightforward. When the superior vena cava is blocked, catheters inserted through the arm or the neck cannot reach the heart reliably, and passing a catheter through the obstructed segment risks worsening thrombosis or failing entirely. The femoral vein, by contrast, drains through the inferior vena cava, a completely separate highway back to the heart that typically remains patent even in patients with severe chest disease. Tunneled catheters add a further layer of protection: the catheter is inserted at the thigh but routed through a subcutaneous tunnel before exiting the skin some distance away, a design intended to keep skin bacteria from migrating along the catheter shaft into the bloodstream. Until now, however, robust prospective data on how these devices actually perform over weeks and months of cancer treatment has been scarce, leaving clinicians to make decisions based largely on small retrospective series.

The research team, led by Zhen-Ming Wu, Chun-Li Huang, Ze-Yin Hu, and Jia Li, enrolled 89 adult oncology patients diagnosed with superior vena cava syndrome who received TFICCs at their center between March and June 2022. The study was registered prospectively with the Chinese Clinical Trial Registry before recruitment began, and it followed a predefined protocol tracking a battery of complications: catheter dislodgement, occlusion, abnormal blood reflux, catheter-associated skin injury, thrombosis, and unplanned removal. The researchers also collected detailed anatomical and demographic measurements, including thigh circumference, catheter length, indwelling duration, and catheter type, and then used logistic regression to identify which factors predicted which complications. This combination of prospective design and multivariable analysis is what distinguishes the study from much of the prior literature, which often simply reported raw complication rates without probing the underlying risk factors.

The headline result is a mixed blessing. Nearly half of the patients, 47.2 percent, experienced at least one TFICC-related complication during the catheter’s dwell time. Yet the severity of those complications was often modest, and the most feared problems were rare. Only 5.6 percent of catheters, five out of 89, had to be removed ahead of schedule because of complications, meaning that the overwhelming majority of devices stayed in place long enough to complete their intended purpose of delivering chemotherapy and other intravenous therapies. Infection rates and catheter-related thrombosis, the two complications that most often doom central lines in immunocompromised cancer patients, were both low, lending support to the idea that the tunneled femoral route is a genuinely viable long-term option when the upper body is off limits.

The single most common complication, however, was dislodgement, which affected 23.6 percent of patients, or 21 of the 89 enrolled. In other words, nearly one in four catheters partially or fully migrated out of position, a rate the authors flag as unacceptably high and as the clearest signal in their data that securement techniques for femoral lines need reinvention. Catheters placed in the thigh face a unique mechanical challenge: the hip and knee flex with every step, subjecting the catheter and its dressing to constant flexion, shear, and moisture from perspiration, forces that upper-arm catheters rarely endure. The finding suggests that the engineering problem is not the catheter itself but its interface with a moving, sweating, weight-bearing part of the body.

The regression analysis yielded several practical insights that could change how these catheters are selected and managed. Catheter design mattered for occlusion: patients who received Groshong catheters, which feature a valve at the distal tip of the catheter, had roughly a 90 percent lower odds of occlusion compared with those receiving proximal-valve models such as the Power PICC SOLO, with an odds ratio of 0.098. Male sex was also protective against occlusion, with an odds ratio of 0.068, a finding that may reflect anatomical differences in vein diameter or flow dynamics. The authors suggest that distal-valve catheters may be particularly advantageous for ambulatory patients, whose constant movement appears to stress proximal-valve designs more severely.

Geometry and time also shaped the risk profile in measurable ways. Each additional centimeter of catheter length reduced the odds of dislodgement, with an odds ratio of 0.685 per unit increase, implying that longer subcutaneous tunnels anchor the device more securely and resist the pulling forces generated by limb movement. Conversely, every extra day the catheter remained in place slightly increased dislodgement risk, with an odds ratio of 1.009 per day, a small per-day effect that accumulates meaningfully over the weeks of a typical chemo regimen. Meanwhile, patients with larger thigh circumferences were more likely to experience abnormal blood reflux, with an odds ratio of 1.168 per unit increase, possibly because greater soft-tissue bulk alters the fit of the catheter within the vein or changes local hemodynamics around the tip.

For oncologists and vascular access teams, the study arrives at a moment when demand for alternative access routes is growing. Superior vena cava syndrome is most commonly caused by lung cancer, lymphoma, and metastatic disease, and as cancer survival improves, more patients need reliable central venous access for extended periods despite central chest obstruction. The data suggest a practical decision framework: choose a distal-valve Groshong catheter when the patient will be walking around, tunnel the catheter as long as anatomy allows, monitor closely as dwell time extends, and pay special attention to securement in patients with larger thighs. None of these adjustments requires new technology, only a more deliberate application of what the cohort data now show.

The study does have limitations worth keeping in view. With 89 patients at a single center, the confidence intervals around some of the risk-factor estimates are wide, and the logistic regression models, while adjusted for multiple variables, cannot fully exclude residual confounding. The cohort was assembled over a concentrated four-month window in 2022, and practice patterns at one high-volume Chinese cancer center may not generalize everywhere. Still, the prospective registration, the systematic complication tracking, and the multivariable analysis represent a meaningful upgrade over the retrospective chart reviews that have dominated this field. The authors’ conclusion is measured but clear: TFICCs deliver low infection and thrombosis rates in patients with superior vena cava syndrome, but the 23.6 percent dislodgement rate is a call to action for better securement techniques, and distal-valve catheter designs deserve preference in mobile patients. For the growing population of cancer patients whose anatomy rules out conventional access, that combination of reassurance and specific engineering guidance is exactly what clinical practice has been waiting for.

Subject of Research: Long-term complications of tunneled femoral inserted central catheters in adult oncology patients with superior vena cava syndrome

Article Title: Assessment of long-term complications in adult oncology patients with superior vena cava syndrome receiving tunneled femoral inserted central catheters: a prospective cohort study

Article References: Wu, Z.-M., Huang, C.-L., Hu, Z.-Y., Luo, M.-N., Fan, Y.-Y., & Li, J. (2026). Assessment of long-term complications in adult oncology patients with superior vena cava syndrome receiving tunneled femoral inserted central catheters: a prospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-16444-x

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16444-x

Keywords: superior vena cava syndrome, tunneled femoral inserted central catheter, central venous access, oncology, catheter dislodgement, catheter occlusion, Groshong catheter, thrombosis, prospective cohort study, vascular access, catheter securement, BMC Cancer